The update was requested by the FDA based on data supporting the significant LDL-C lowering abilities of PCSK-targeting therapies.

The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein ...

Novartis announced the FDA approved updated labeling for inclisiran, a small-interfering RNA therapy, for use as monotherapy ...

Shares of European pharmaceutical companies sold off on Friday after President Donald Trump sent letters to 17 companies, including U.S. firms, in the sector.

The Senate Appropriations Committee rejected the Trump administration's proposed $18 billion cuts to NIH and associated ...

Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® (inclisiran), enabling its use as monotherapy along with diet and exercise to reduce low ...

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.